Hypophosphatemia, Kidney Transplantation
Conditions
Keywords
Post-kidney transplant care, Dipyridamole, Renal phosphate loss, Serum phosphate levels, Phosphate supplementation, Transplant graft function, Kidney transplant complications
Brief summary
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Interventions
Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult kidney transplant patients. * No known contraindications to Dipyridamole
Exclusion criteria
* Contraindications to Dipyridamole. * Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Serum Phosphorus Levels After Dipyridamole Administration | Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio | This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORStephan Busque, MD
Stanford University
Outcome results
None listed